Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial.

Auteurs : de Azambuja E, Agostinetto E, Procter M, Eiger D, Pondé N, Guillaume S, Parlier D, Lambertini M, Desmet A, Caballero C, Aguila C, Jerusalem G, Walshe JM, Frank E, Bines J, Loibl S, Piccart-Gebhart M, Ewer MS, Dent S, Plummer C, Suter T
Année : 2023
Journal : ESMO Open
Volume : 8
Pages : 100772

Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer.

Auteurs : Nuciforo P, Townend J, Piccart-Gebhart M, Fielding S, Gkolfi P, El-Abed S, de Azambuja E, Werutsky G, Bliss J, Moebus V, Colleoni M, Aspitia AM, Gomez H, Gombos A, Coccia-Portugal MA, Tseng LM, Kunz G, Lerzo G, Sohn J, Semiglazov V, Saura C, Kroep J, Ferro A, Cameron D, Gelber R, Huober J, Di Cosimo S
Année : 2023
Journal : Eur J Cancer
Volume : 181
Pages : 92-101

Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer.

Auteurs : Lambertini M, Ceppi M, Anderson RA, Cameron DA, Bruzzone M, Franzoi MA, Massarotti C, El-Abed S, Wang Y, Lecocq C, Nuciforo P, Rolyance R, Pusztai L, Sohn J, Latocca MM, Arecco L, Pistilli B, Ruddy KJ, Ballestrero A, Del Mastro L, Peccatori FA, Partridge AH, Saura C, Untch M, Piccart-Gebhart M, Di Cosimo S, de Azambuja E, Demeestere I
Année : 2023
Journal : J Natl Compr Canc Netw
Volume : 21
Pages : 33-41.e16

Medical oncology education in Europe: equipping medical oncologists to provide the best care for patients with cancer.

Auteurs : Jordan K, de Azambuja E, Amaral T, Strijbos M, Curigliano G, Lordick F
Année : 2023
Journal : Oncol Res Treat

Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate.

Auteurs : Poggio F, Tagliamento M, Ceppi M, Bruzzone M, Conte B, Fregatti P, Punie K, de Azambuja E, Del Mastro L, Lambertini M
Année : 2022
Journal : Ann Oncol
Volume : 33
Pages : 347-349

De novo Metastatic Breast Cancer Arising in Young Women: Review of the Current Evidence.

Auteurs : Conte B, Soldato D, Razeti MG, Fregatti P, de Azambuja E, Schettini F, Prat A, Del Mastro L, Lambertini M
Année : 2022
Journal : Clin Breast Cancer
Volume : 22
Pages : 78-87

Correction to: Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub‑analysis of the ALTTO trial (BIG 2‑06; NCCTG (Alliance) N063D).

Auteurs : Pondé N, Agbor-Tarh D, Dal Lago L, Korde LA, Hilbers F, Jackisch C, Werner O, Gelber Rd, Jatoi A, Dueck AC, Moreno-Aspitia A, Sotiriou C, de Azambuja E, Piccart M
Année : 2022
Journal : Breast Cancer Res Treat
Volume : 191
Pages : 225

Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab.

Auteurs : Ligorio F, Di Cosimo S, Verderio P, Ciniselli CM, Pizzamiglio S, Castagnoli L, Dugo M, Galbardi B, Salgado R, Loi S, Michiels S, Triulzi T, Tagliabue E, El-Abed S, Izquierdo M, de Azambuja E, Nuciforo P, Huober J, Moscetti L, Janni W, Coccia-Portugal MA, Corsetto PA, Belfiore A, Lorenzini D, Daidone MG, Vingiani A, Gianni L, Pupa SM, Bianchini G, Pruneri G, Vernieri C
Année : 2022
Journal : J Natl Cancer Inst
Volume : 114
Pages : 1720-1727

Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel.

Auteurs : Arboleda B, Bartsch R, de Azambuja E, Hamilton E, Harbeck N, Klemp J, Knauer M, Kuemmel S, Mahtani R, Schwartzberg L, Villarreal-Garza C, Wolff A
Année : 2022
Journal : Oncologist
Volume : 27
Pages : 722-731

PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer.

Auteurs : Agostinetto E, Ameye L, Martel S, Aftimos P, Pondé N, Maurer C, El-Abed S, Wang Y, Vicente M, Chumsri S, Bliss J, Kroep J, Colleoni M, Petrelli F, Del Mastro L, Moreno-Aspitia A, Piccart M, Paesmans M, de Azambuja E, Lambertini M
Année : 2022
Journal : NPJ Breast Cancer
Volume : 8
Pages : 87

Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis.

Auteurs : Martins-Branco D, Nader-Marta G, Tecic Vuger A, Debien V, Ameye L, Brandão M, Punie K, Loizidou A, Willard-Gallo K, Spilleboudt C, Awada A, Piccart M, de Azambuja E
Année : 2022
Journal : J Cancer Res Clin Oncol
Pages : 1-6

Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis.

Auteurs : Nader-Marta G, Martins-Branco D, Agostinetto E, Bruzzone M, Ceppi M, Danielli L, Lambertini M, Kotecki N, Awada A, de Azambuja E
Année : 2022
Journal : ESMO Open
Volume : 7
Pages : 100501

Anthracyclines in the treatment of patients with early breast cancer.

Auteurs : Guarneri V, de Azambuja E
Année : 2022
Journal : ESMO Open
Volume : 7
Pages : 100461

Timelines to initiate a phase III trial across the globe: a sub-analysis of the APHINITY trial.

Auteurs : Franzoi MA, Procter M, Twelves C, Ponde N, Eiger D, Emond O, Clark E, Parlier D, Guillaume S, Reaby L, de Azambuja E, Bines J
Année : 2022
Journal : Ecancermedicalscience
Volume : 16
Pages : 1379

Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy-a sub-analysis of the ALTTO study.

Auteurs : Nader-Marta G, Debien V, Eiger D, Tsourti Z, Caparica R, Kassapian M, Napoleone S, Hultsch S, Korde L, Wang Y, Chumsri S, Pritchard KI, Untch M, Bellet-Ezquerra M, Dornelles Rosa D, Moreno-Aspitia A, Piccart M, Dafni U, de Azambuja E
Année : 2022
Journal : Br J Cancer
Volume : 127
Pages : 1799-1807

Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.

Auteurs : Agostinetto E, Losurdo A, Nader-Marta G, Santoro A, Punie K, Barroso R, Popovic L, Solinas C, Kok M, de Azambuja E, Lambertini M
Année : 2022
Journal : Expert Opin Investig Drugs
Volume : 31
Pages : 567-591

Implication of body mass index (BMI) on the biological and clinical effects of endocrine therapy plus abemaciclib as neoadjuvant therapy for early breast cancer patients.

Auteurs : Franzoi MA, Lambertini M, Ceppi M, Bruzzone M, de Azambuja E
Année : 2022
Journal : Breast Cancer Res Treat
Volume : 192
Pages : 457-462

Authors' Reply To the Letters to the Editor by Puklin et al and by Iyengar and Ligibel.

Auteurs : Martel S, Lambertini M, de Azambuja E
Année : 2022
Journal : J Natl Compr Canc Netw
Volume : 20
Pages : xlv-xlvi

How we treat patients with metastatic HER2-positive breast cancer.

Auteurs : Nader-Marta G, Martins-Branco D, de Azambuja E
Année : 2022
Journal : ESMO Open
Volume : 7
Pages : 100343

Evaluation of Cardiotoxicity in HER-2-Positive Breast Cancer Patients Treated With Radiation Therapy and Trastuzumab.

Auteurs : Bachir B, Anouti S, Abi Jaoude J, Kayali M, Tfayli A, de Azambuja E, Poortmans P, Zeidan YH
Année : 2022
Journal : Int J Radiat Oncol Biol Phys
Volume : 113
Pages : 135-142